

Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) - Pipeline Review, H1 2018

<https://marketpublishers.com/r/H6172E4B4E6EN.html>

Date: June 2018

Pages: 29

Price: US\$ 3,500.00 (Single User License)

ID: H6172E4B4E6EN

Abstracts

Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) - Pipeline Review, H1 2018

SUMMARY

Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) - Euchromatic histone-lysine N-methyltransferase 2 (EHMT2) is a histone methyltransferase encoded by the EHMT2 gene. It mediates monomethylation of 'Lys-56' of histone H3 (H3K56me1) in G1 phase, leading to promote interaction between histone H3 and PCNA and regulating DNA replication. It weakly methylates 'Lys-27' of histone H3 (H3K27me). It is required for DNA methylation.

Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) pipeline Target constitutes close to 6 molecules. Out of which approximately 2

molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Preclinical and Discovery stages are 1 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 4 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Gastrointestinal and Hematological Disorders which include indications Malaria, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Colon Cancer, Hepatocellular Carcinoma, Leukemias, Liver Fibrosis, Lymphoma and Sickle Cell Disease.

The latest report Histone Lysine N Methyltransferase EHMT2 - Pipeline Review, H1 2018, outlays comprehensive information on the Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43)

The report reviews Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) targeted therapeutics and enlists all their major and minor projects

The report assesses Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to

formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N

Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9

Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC

2.1.1.43) - Overview

Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N

Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9

Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC

2.1.1.43) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N

Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9

Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC

2.1.1.43) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N

Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9

Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC

2.1.1.43) - Companies Involved in Therapeutics Development

Domainex Ltd

Epizyme Inc

Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N

Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9

Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC

2.1.1.43) - Drug Profiles

BIX-01294 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CM-272 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EZM-8266 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit G9a Protein for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TM-2115 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

verticillin A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N

Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9

Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC

2.1.1.43) - Dormant Products

Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N

Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9

Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC

2.1.1.43) - Product Development Milestones

Featured News & Press Releases

Dec 11, 2017: Epizyme Presents Preclinical Data on Novel G9a Program and Introduces Next Drug Development Candidate at the American Society of Hematology Annual Meeting

Oct 24, 2012: New Opportunity For Rapid Treatment Of Malaria

Sep 27, 2012: Malaria Takes a Hit-Two New Molecules Stop P. falciparum In Its Tracks

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

[Contact Us](#)
[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Domainex Ltd, H1 2018

Pipeline by Epizyme Inc, H1 2018

Dormant Projects, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

COMPANIES MENTIONED

Domainex Ltd

Epizyme Inc

I would like to order

Product name: Histone Lysine N Methyltransferase EHMT2 (Euchromatic Histone Lysine N Methyltransferase 2 or HLA B Associated Transcript 8 or Histone H3 K9 Methyltransferase 3 or Lysine N Methyltransferase 1C or Protein G9a or EHMT2 or EC 2.1.1.43) - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/H6172E4B4E6EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H6172E4B4E6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970